Treace Medical Concepts, Inc. TMCI
4.78 USD +0.75 (+18.61%)
At closeNov 9, 2026, 4:00 PM EST
4.78 0.00 0.00%
After hours · Nov 9, 4:00 PM ET
4.48 Day range 5.22
1.17 52-week range 5.25
- YTD
- +95.10%
- 1 year
- +6.94%
News
benzinga.com This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Analysts upgraded Treace Medical, AMD, Airbnb, and/or price targets.
benzinga.com Stifel Upgrades Treace Medical Concepts to Buy, Raises Price Target to $6.5 Stifel analyst Rick Wise upgrades Treace Medical Concepts (NASDAQ:TMCI) from Hold to Buy and raises the price target from $4.5 to $6.5.
seekingalpha.com Treace Medical Concepts, Inc. (TMCI) Q3 2026 Earnings Call Transcript Treace Medical Concepts, Inc. ( TMCI ) Q3 2026 Earnings Call November 6, 2026 8:00 AM EST Company Participants Trip Taylor John Treace - Founder, Chairman & CEO Mark Hair - Chief Financial Officer…
zacks.com Treace Medical Concepts (TMCI) Reports Q3 Loss, Tops Revenue Estimates Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.26 per share a year ago.
benzinga.com Treace Medical Concepts Q3 2026 Earnings Call Transcript Treace Medical Concepts (NASDAQ:TMCI) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Treace Medical Concepts Narrows FY2026 Sales Guidance from $204.000M-$212.000M to $206.000M-$210.000M vs $207.488M Est Treace Medical Concepts (NASDAQ:TMCI) narrows FY2026 sales outlook from $204.000 million-$212.000 million to $206.000 million-$210.000 million vs $207.488 million estimate.
globenewswire.com Treace Medical Concepts Reports Third Quarter 2026 Financial Results PONTE VEDRA, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company with the goal of being the recognized…
globenewswire.com Treace Announces First Surgical Cases with the Tailorplasty™ MIS Tailor's Bunion Correction System New solution for 5ᵗʰ metatarsal deformities further broadens portfolio and provides access to incremental surgical procedures New solution for 5ᵗʰ metatarsal deformities further broadens portfolio…
globenewswire.com Treace to Present at the Stifel 2026 Healthcare Conference PONTE VEDRA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday's pre-market session. Lipocine (NASDAQ:LPCN) shares rose 52.38% to $3.2. The company's market cap…
benzinga.com Treace Medical Presents 5-Year ALIGN3D Data Showing 0.8% Recurrence Rate Alongside MTA3D And SPRINT Clinical Results At AOFAS 2026 Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle- benzinga.com Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $5 Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $4 to $5.
benzinga.com Treace Medical Concepts Q2 EPS $(0.24) Beats $(0.30) Estimate, Sales $45.376M Beat $44.020M Estimate Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.30) by 20 percent. This is a 14.29 percent increase over losses…- benzinga.com Treace Medical Concepts Raises FY2026 Sales Guidance from $202.000M-$212.000M to $204.000M-$212.000M vs $206.220M Est Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $202.000 million-$212.000 million to $204.000 million-$212.000 million vs $206.220 million estimate.
benzinga.com Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $4 Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $2 to $4.- benzinga.com Treace Medical Concepts Announces Completion Of First Case Utilizing Its HyperPlate XM Dynamic Compression Locking Implant, Complete Commercialization Expected in Q3 of 2026 HyperPlate™ fixation technology further advances the SpeedPlate® implant platform by incorporating FastPitch® locking screws into the titanium compression implants to deliver rapid insertion and…
benzinga.com Treace Medical Concepts Raises FY2026 Sales Guidance from $200.000M-$212.000M to $202.000M-$212.000M vs $205.920M Est Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $200.000 million-$212.000 million to $202.000 million-$212.000 million vs $205.920 million estimate.- benzinga.com Treace Medical Concepts Q1 EPS $(0.28) Beats $(0.31) Estimate, Sales $47.198M Beat $45.960M Estimate Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 12 percent decrease over losses of…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session 
benzinga.com US Stocks Mixed; Dow Falls Over 100 Points US stocks mixed; Dow falls 0.29% as inflation rate surges to 3.3%. Materials up 0.8%, financials down 0.8%. Asian markets close higher.- benzinga.com Lake Street Maintains Buy on Treace Medical Concepts, Lowers Price Target to $7 Lake Street analyst Ben Haynor maintains Treace Medical Concepts (NASDAQ:TMCI) with a Buy and lowers the price target from $7.5 to $7.
- benzinga.com Treace Medical Concepts Sees FY2026 Sales $200.000M-$212.000M vs $210.335M Est 2026 Financial OutlookThe Company is initiating full-year 2026 revenue guidance of $200 million to $212 million representing a decline of 6% to 0% compared to full-year 2025.The Company expects a…
benzinga.com Treace Medical Concepts Q4 Earnings Summary & Key Takeaways - benzinga.com Treace Medical Concepts Q4 EPS $(0.15), Inline, Sales $62.519M Beat $61.390M Estimate Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 1400 percent decrease over losses of $(0.01) per share from…
benzinga.com Earnings Scheduled For February 27, 2026 
benzinga.com Treace Medical Concepts's Earnings: A Preview - benzinga.com Treace Medical Concepts Completes First Case Utilizing Its Lapiplasty Lightning Technology Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot…
- benzinga.com The Analyst Verdict: Treace Medical Concepts In The Eyes Of 6 Experts
- benzinga.com Stifel Maintains Hold on Treace Medical Concepts, Lowers Price Target to $3 Stifel analyst Rick Wise maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price target from $5 to $3.
benzinga.com Truist Securities Maintains Hold on Treace Medical Concepts, Lowers Price Target to $3 Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price target from $4 to $3.- benzinga.com Treace Medical Enters Into New Five Year $175M Senior Secured Loan Arrangement With Credit Funds Managed By SLR Capital Partners Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities,…
- benzinga.com Truist Securities Reiterates Hold on Treace Medical Concepts, Lowers Price Target to $4 Truist Securities analyst Richard Newitter reiterates Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price target from $7 to $4.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Nasdaq Tumbles Over 100 Points; US Consumer Sentiment Falls In November 
benzinga.com UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $5.85 UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and lowers the price target from $6.5 to $5.85.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com JP Morgan Downgrades Treace Medical Concepts to Underweight, Lowers Price Target to $5 JP Morgan analyst Lilia-Celine Lozada downgrades Treace Medical Concepts (NASDAQ:TMCI) from Neutral to Underweight and lowers the price target from $8 to $5.
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Block Posts Downbeat Q3 Results, Joins Archer Aviation, DraftKings And Other Big Stocks Moving Lower In Friday's Pre-Market Session - benzinga.com Treace Medical Concepts Lowers FY2025 Sales Guidance from $224.000M-$230.000M to $211.000M-$213.000M vs $227.083M Est Treace Medical Concepts (NASDAQ:TMCI) lowers FY2025 sales outlook from $224.000 million-$230.000 million to $211.000 million-$213.000 million vs $227.083 million estimate.
- benzinga.com Treace Medical Concepts Q3 EPS $(0.26) Beats $(0.28) Estimate, Sales $50.214M Beat $49.732M Estimate Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 4 percent decrease over losses of…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Truist Securities Maintains Hold on Treace Medical Concepts, Lowers Price Target to $7 Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price target from $8 to $7.
- benzinga.com Truist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $8 Truist Securities analyst Richard Newitter maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and raises the price target from $6.6 to $8.
- benzinga.com UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $6.5 UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Neutral and lowers the price target from $8.6 to $6.5.
- benzinga.com Stifel Maintains Hold on Treace Medical Concepts, Lowers Price Target to $6 Stifel analyst Rick Wise maintains Treace Medical Concepts (NASDAQ:TMCI) with a Hold and lowers the price target from $9 to $6.
- benzinga.com Treace Medical Concepts Affirms FY2025 Sales Guidance of $224.000M-$230.000M vs $227.030M Est Treace Medical Concepts (NASDAQ:TMCI) affirms FY2025 sales outlook from $224.000 million-$230.000 million to $224.000 million-$230.000 million vs $227.030 million estimate.
- benzinga.com Treace Medical Concepts Q2 EPS $(0.28) Beats $(0.29) Estimate, Sales $47.387M Beat $47.077M Estimate Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 2.78 percent. This is a 17.65 percent increase over losses…
- benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com Treace Medical Concepts Announces Peer-Reviewed Publication Of The 4-Year Interim Results From Its ALIGN3D Multicenter Prospective Study Demonstrating Clinical And Radiographic Outcomes Of The Lapiplasty Procedure In The Journal Of Foot & Ankle Surgery Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities,…